Difference between revisions of "Ramosetron (Iribo)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "5HT3" to "5-HT3") |
m |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
| − | Serotonin 5-HT3 receptor antagonist with antiemetic properties. No known antineoplastic properties. | + | Serotonin 5-HT3 receptor antagonist with antiemetic properties. No known antineoplastic properties. Not FDA-approved; available in Japan and Southeast Asia. |
| − | |||
| − | |||
| − | Not FDA-approved; available in Japan and Southeast Asia. | ||
==Also known as== | ==Also known as== | ||
| − | IBset, Nasea, Nozia | + | *'''Brand names:''' IBset, Iribo, Irribow, Nasea, Nozia |
| − | [[Category: | + | [[Category:Drugs]] |
| + | [[Category:Oral medications]] | ||
| + | [[Category:Intravenous medications]] | ||
[[Category:Emesis prevention]] | [[Category:Emesis prevention]] | ||
[[Category:Serotonin 5-HT3 antagonists]] | [[Category:Serotonin 5-HT3 antagonists]] | ||
| + | [[Category:PMDA approved in 2015]] | ||
Latest revision as of 01:27, 11 June 2023
Mechanism of action
Serotonin 5-HT3 receptor antagonist with antiemetic properties. No known antineoplastic properties. Not FDA-approved; available in Japan and Southeast Asia.
Also known as
- Brand names: IBset, Iribo, Irribow, Nasea, Nozia